How Do I Find Biotech Companies Entering Phase 2 or Phase 3?

ClinicalTrials.gov records study phase and recruitment status as separate fields: a change to "Recruiting" is not a phase transition. Find credible Phase 2 or Phase 3 movement by combining a study's phase, start dates and record history with sponsor announcements or filings, then label the evidence precisely and filter it for fit.

9 min readUpdated Jul 20, 2026

Key takeaways

ClinicalTrials.gov stores study phase separately from overall and site recruitment status; do not infer one from the other.
A new or updated Phase 2 or Phase 3 record is evidence about a study record, not automatic proof that a company just advanced a program.
Confirm timing with start dates, record history, and a sponsor announcement or filing before calling something a transition.
Keep the source, observed date, and exact claim attached to every signal so sellers can distinguish fact from inference.

Finding Phase 2 or Phase 3 study records is straightforward. Establishing that a company is entering that phase requires more care: the registry's phase, recruitment status, dates, and record history are separate data, and a sponsor announcement or filing may be needed to corroborate the timing.

Separate study phase from recruitment status
Start with the exact fields, because they are not interchangeable. ClinicalTrials.gov stores study phase under the design module and overall recruitment status under the status module. A Phase 2 study can be not yet recruiting, recruiting, active but not recruiting, completed, or another status without changing phase.
Registry phase and dates
ClinicalTrials.gov records study phase in the design module and recruitment status in the status module. Read phase, start dates, record history, and last verification separately; a recruitment-status change is not a phase change.
Company announcement
A sponsor press release, investor update, or filing may say that a program started or advanced and can corroborate the timing and wording of the company-level claim.
Regulatory or financing context
A regulatory or financing update may mention the planned study stage, but it should be treated as context unless it directly states that the new study has started.
Read together, these sources support a carefully worded account of what is public. They do not prove that a procurement process has begun. The clinical trial signals guide covers how to interpret registry and trial activity as an account's operational reality, not just as news.
Decide fit criteria before you search
Before pulling any transitions, write down what makes a phase-transitioning company a fit for what you sell, so you are filtering toward relevant accounts rather than collecting every transition everywhere. The criteria that usually matter most:
- Therapeutic area, if your work is concentrated in particular indications.
- Modality, which matters especially for manufacturing, where capability is highly specific.
- Company size and type, since an early-stage biotech and a large sponsor are different buyers.
- Serviceable stage, so you only keep transitions where your service is actually relevant.
Deciding this first is what keeps the next steps from producing a long, noisy list. See how to build a target account list from one customer for a way to derive these criteria concretely from an account you already serve well.
Corroborate the timing
A list of Phase 2 or Phase 3 records is a useful starting point, but it does not establish when a company advanced. Check whether the date is anticipated or actual, inspect the record history, and look for a first-party statement that uses the same phase and program.
ClinicalTrials.gov also notes that sponsors or investigators submit and maintain study information, while NLM performs only a limited quality-control review. Preserve the source and last-verified date so the record can be checked rather than presented as an independently verified company event.
Filter the evidence down to fit
Run the corroborated study activity against the fit criteria from step two and drop everything that does not clear them, companies outside your modality, outside your therapeutic focus, or at a stage where your service is not relevant. What remains is a shorter list of accounts where the observed study activity merits further research.
Fit is the gate that makes study activity worth investigating. Activity at a company you cannot serve is not an opportunity no matter how clear the activity is. See how to score account fit for the filtering layer.
State only what the evidence shows
A recent, corroborated study update can be a specific reason to research an account or start a relevant conversation. It is not evidence that the company has budget, is selecting vendors, or will outsource the work.
- Name the study, reported phase, and date rather than saying a company "just transitioned."
- Distinguish an anticipated start date from an actual start date.
- Keep uncorroborated records on a research list until another source confirms the timing.
For why timing beats persistence here, and how a transition's relevance decays, see timing outreach with readiness signals. For what a transition tends to trigger in the way of an actual purchase, see when biotech companies buy CRO and CDMO services.

Checklist

Study phase read separately from overall and site recruitment status.
Fit criteria written down before searching, so the list filters toward relevant accounts.
Study dates and record history checked before making a timing claim.
Company-level movement corroborated with a first-party announcement or filing.
Every note retains its source, observed date, and exact wording.

Where Arcova fits: Arcova can surface phase-labeled study activity for accounts that fit your ICP and preserve the underlying evidence for review. The source record still needs to support the wording used: recruitment status is not clinical phase, and neither field proves that a vendor decision is underway.

Primary sources

ClinicalTrials.gov study data structure defines study phase and recruitment status as separate fields.
ClinicalTrials.gov disclaimer explains who submits study information and the limits of NLM review.

Frequently asked questions

Where do phase transitions actually show up publicly?

ClinicalTrials.gov exposes a study-phase field, planned and actual dates, recruitment status, and record history. Those fields answer different questions: recruitment status says whether a study is enrolling, while phase describes the study design. A sponsor announcement, SEC filing, or other first-party update can corroborate whether the company describes the program as starting or advancing. Use the sources together and preserve the distinction between a registry record and a company-level transition.

Can I just pull a one-time list of companies in Phase 2?

You can, but it answers which registered studies carry a Phase 2 label, not which companies just advanced. Some records are estimates, some are updated after the underlying event, and sponsors are responsible for the submitted information. To make a timing claim, inspect the study dates and version history and seek first-party corroboration.

Why filter for fit instead of contacting everyone entering a phase?

Because study activity is relevant only when the account, program, modality, geography, and service need fit what you can deliver. Filtering first turns a broad registry result into a research list. It still does not turn a study record into proof of a purchase.

How fresh does a transition need to be to act on it?

There is no universal sales window. Record the source date, the study's reported start date, and when the sponsor last verified the record. A recent, corroborated update can justify research or a relevant conversation; it does not by itself establish urgency, budget, or an active vendor search.

Do I need a tool to do this, or can I do it by hand?

You can inspect a small set of study records and sponsor updates manually. At larger scale, tooling can detect changes and retain source dates, but a human-readable evidence trail remains important because field changes require interpretation and corroboration.